Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11 - 30; http://dx.doi.org/10.3322/caac.21166; PMID: 23335087
   PubMed Web of Science ®Google Scholar
• Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol 2013; 23:331 - 6; http://dx.doi.org/10.1097/MOU.0b013e328361d48e; PMID: 23619582
   PubMed Web of Science ®Google Scholar
• Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 2010; 8:145; PMID: 20141674
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26:2497 - 504; http://dx.doi.org/10.1200/JCO.2007.14.9021; PMID: 18413638
   PubMed Web of Science ®Google Scholar
• Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, et al, EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360:2516 - 27; http://dx.doi.org/10.1056/NEJMoa0810095; PMID: 19516032
   PubMed Web of Science ®Google Scholar
• Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11:1066 - 73; http://dx.doi.org/10.1016/S1470-2045(10)70223-0; PMID: 20933466
   PubMed Web of Science ®Google Scholar
• Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. Int J Radiat Oncol Biol Phys 2013; 86:721 - 8; http://dx.doi.org/10.1016/j.ijrobp.2013.03.028; PMID: 23664325
   PubMed Web of Science ®Google Scholar
• Choe KS, Liauw SL. Effects of aspirin on cancer initiation and progression. Expert Rev Anticancer Ther 2013; 13:115 - 7; http://dx.doi.org/10.1586/era.12.166; PMID: 23406550
   PubMed Web of Science ®Google Scholar
• Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer 2010; 116:1820 - 6; http://dx.doi.org/10.1002/cncr.24890; PMID: 20143436
   PubMed Web of Science ®Google Scholar
• Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012; 30:3540 - 4; http://dx.doi.org/10.1200/JCO.2011.41.0308; PMID: 22927523
   PubMed Web of Science ®Google Scholar
• Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, et al, PROSTQA Consortium Study Group. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys 2013; 86:546 - 53; http://dx.doi.org/10.1016/j.ijrobp.2013.01.036; PMID: 23561651
   PubMed Web of Science ®Google Scholar
• Choe KS, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?. Int J Radiat Oncol Biol Phys 2010; 76:755 - 60; http://dx.doi.org/10.1016/j.ijrobp.2009.02.026; PMID: 19464123
   PubMed Web of Science ®Google Scholar
• Moon CM, Kwon JH, Kim JS, et al. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. Int J Cancer 2014; 134:519 29; http://dx.doi.org/10.1002/ijc.2838; PMID: 23852449
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao Y, Liu Y, Akiyama K, Chen C, Qu C, Jin Y, Shi S. IFN-γ and TNF-α synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFκB signaling. Stem Cells 2013; 31:1383 - 95; http://dx.doi.org/10.1002/stem.1388; PMID: 23553791
   PubMed Web of Science ®Google Scholar
• Khor L-Y, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 2007; 8:912 - 20; http://dx.doi.org/10.1016/S1470-2045(07)70280-2; PMID: 17881290
   PubMed Web of Science ®Google Scholar
• Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006; 12:2172 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-05-2067; PMID: 16609031
   PubMed Web of Science ®Google Scholar
• Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24:2723 - 8; http://dx.doi.org/10.1200/JCO.2005.03.7804; PMID: 16782912
   PubMed Web of Science ®Google Scholar
• Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 2004; 93:275 - 8; http://dx.doi.org/10.1111/j.1464-410X.2004.04601.x; PMID: 14764122
   PubMed Web of Science ®Google Scholar
• Saha D, Pyo H, Choy H. COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer. Am J Clin Oncol 2003; 26:S70 - 4; http://dx.doi.org/10.1097/01.COC.0000074161.92815.93; PMID: 12902860
   PubMedGoogle Scholar
• Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012; 9:259 - 67; http://dx.doi.org/10.1038/nrclinonc.2011.199; PMID: 22473097
   PubMed Web of Science ®Google Scholar
• Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer 2009; 115:4470 - 6; http://dx.doi.org/10.1002/cncr.24526; PMID: 19637339
   PubMed Web of Science ®Google Scholar
• Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer 2006; 107:2392 - 400; http://dx.doi.org/10.1002/cncr.22261; PMID: 17041884
   PubMed Web of Science ®Google Scholar
• Russo AL, Chen MH, Aizer AA, Hattangadi JA, D’Amico AV. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM). BJU Int 2012; 110:973 - 9; http://dx.doi.org/10.1111/j.1464-410X.2012.11470.x; PMID: 22954029
   PubMed Web of Science ®Google Scholar
• Roach M 3rd, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965 - 74; http://dx.doi.org/10.1016/j.ijrobp.2006.04.029; PMID: 16798415
   PubMed Web of Science ®Google Scholar